Detailed Narrative
Strong Financial Performance and Margin Expansion
Laurus Labs reported a robust Q3 FY26 with revenues of ₹1,778 crores, marking a 26% year-on-year growth. The nine-month period saw revenues cross ₹5,001 crores, a 30% increase, with Profit After Tax surging by 388% to ₹610 crores. Gross margins were maintained at approximately 60% (60.9% in Q3), and EBITDA margins expanded to over 27% (27% in Q3), driven by a favorable product and division mix and process improvements. The company's Return on Capital Employed (ROCE) improved to 18.5%.
CDMO Business Dynamics and Future Outlook
The CDMO segment demonstrated strong cumulative 9-month growth exceeding 50%, fueled by recurring business from long-term customer relationships. While Q3 small molecule sales were ₹408 crores, management noted sequential lumpiness due to the timing of deliveries for some programs, which are often once or twice a year. Despite this, a healthy growth trajectory is expected for FY27, with the majority of revenues anticipated from commercial supplies. Investments continue in large-scale capacity expansion at Vizag and enhanced capabilities in peptides, flow, and high-energy chemistries.
Generics Segment Drives Growth
The generics division delivered strong performance, with Q3 revenues growing 37% to ₹1,327 crores and 9-month sales reaching ₹3,510 crores, up 26%. This growth was primarily attributed to higher ARV volumes and strong off-take of recently launched products in developed markets. Management confirmed the sustainability of these Q3 numbers, supported by optimized API capacity and increasing market share in both API and formulations, with North American formulation and European CMO sales also contributing positively.
Strategic CAPEX and New Modalities
Laurus Labs incurred ₹246 crores in CAPEX during Q3, bringing the 9-month total to ₹735 crores, with a full-year FY26 projection of approximately ₹1,000 crores and over ₹1,000 crores for FY27. These investments are directed towards peptide development, manufacturing infrastructure, and operationalizing antibody drug conjugate (ADC) and gene therapy process development labs. While significant investments are being made in ADCs and gene therapy, no meaningful revenues are expected from these nascent areas in the next 24 months.
Joint Ventures and Capacity Expansion
The company is progressing with its joint venture with Krka Pharma, with Phase-1 of the Hyderabad facility expected to be completed by mid-2027, aiming to manufacture formulations for European markets. Revenues from this JV are anticipated to commence in FY27. Additionally, the commercial-scale fermentation facility at Vizag is on track, with Phase-1 capacity of over 400 kiloliters expected to be operational by the end of 2026. The ImmunoACT/Cipla JV for South Africa is expected to become meaningful from FY28, pending regulatory approvals.
Capital Structure and Efficiency
Net debt stood at ₹2,092 crores, maintaining a similar level to the previous quarter, while the debt-to-EBITDA ratio improved to approximately 1.2x. Management expressed confidence in the company's ability to absorb the annual CAPEX, and while not committing to a 25% ROCE in 12 months, they expect the current 18.5% to improve. The asset turnover currently stands at 0.91, with a long-term target of 1.1.